Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
Genesis Therapeutics
Uses deep learning and molecular simulations to discover small molecule drugs.
What they do
Genesis Therapeutics develops deep learning models for molecular generation and property prediction. The company operates their proprietary platform to design novel small molecule drug candidates against previously undruggable targets, partnering with major pharmaceutical companies.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- Burlingame, United States
- Region
- North America
- Founded
- 2019
- Total funding
- $280M raised
Notable investors: Andreessen Horowitz, Rock Springs Capital, Fidelity Management, T. Rowe Price.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
The Digital Therapeutics Evidence Gap: What FDA Authorization Actually Required
Dr. Dereck Mush, MD, MBA